Prostatype Genomics
0.81 SEK
+1.00 %
Less than 1K followers
PROGEN
First North Stockholm
Medical Equipment & Services
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Valuation
Income statement
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Prostatype Genomics
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 0.1 | 0.7 | 0.0 | 0.7 | 1.4 | 0.2 | 0.6 |
| growth-% | 823.0 % | -98.5 % | 6,700.0 % | 100.0 % | -85.3 % | 197.0 % | |
| EBITDA | -7.7 | -15.8 | -15.5 | -26.8 | -37.4 | -38.9 | -36.8 |
| EBIT | -7.9 | -15.9 | -15.5 | -28.7 | -39.3 | -40.9 | -38.9 |
| Profit before taxes | -8.5 | -17.4 | -15.6 | -29.1 | -41.4 | -41.1 | -44.5 |
| Net income | -8.5 | -17.4 | -15.6 | -29.1 | -41.4 | -41.1 | -44.5 |
| EPS | -33.80 | -68.86 | -54.03 | -69.35 | -89.08 | -3.32 | -1.32 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | -10,414.9 % | -2,308.1 % | -154,600.0 % | -3,939.7 % | -2,747.8 % | -19,435.0 % | -6,187.0 % |
| EBIT-% | -10,623.0 % | -2,329.9 % | -155,480.0 % | -4,219.1 % | -2,886.0 % | -20,425.0 % | -6,555.2 % |
| ROE | -100.0 % | -61.5 % | -43.5 % | -111.2 % | -168.0 % | -122.6 % | -167.8 % |
| ROI | -48.6 % | -51.7 % | -38.9 % | -94.0 % | -84.2 % | -97.8 % | -87.5 % |